Author

Eliza Argonza‐Aviles

Observed names: Argonza-Aviles Eliza, E Argonza-Aviles, E. Argonza-Aviles, Eliza Argonza-Aviles

Observed institutions: Novartis (United States), Institute for Myeloma & Bone Cancer Research

OpenAlex ID: A5072014696

Final 5‐year results of Z‐FAST trial

2011 · Adam M. Brufsky, W. Graydon Harker, et al. · Cancer · 193

The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up.

2009 · A. Brufsky, G. Harker, et al. · Cancer Research · 59

Bone Marker–Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study

2015 · Noopur Raje, Robert Vescio, et al. · Clinical Cancer Research · 54

Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer

2009 · Kishan J. Pandya, Ajeet Gajra, et al. · Lung Cancer · 33

Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial)

2011 · James R. Berenson, Ralph Boccia, et al. · The Journal of Supportive Oncology · 10

Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer.

2010 · F. Andre, J. Baselga, et al. · Journal of Clinical Oncology · 8

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study

2010 · Noopur Raje, Robert Vescio, et al. · Blood · 5

Rheumatologic Evaluation of Adjuvant Letrozole in Post-Menopausal Breast Cancer Patients Discontinuing Anastrozole Due to Grade 2-3 Arthralgia – Myalgia.

2009 · D. Yardley, N. Green, et al. · Cancer Research · 5

Bone-specific alkaline phosphatase (BSAP) and serum N-telopeptide (sNTX) as predictors of bone loss in postmenopausal women with early breast cancer receiving letrozole as adjuvant therapy: a 5-year study (Z-FAST).

2009 · A Brufsky, G Harker, et al. · Cancer Research · 3

Z-fast臨床試験の最終5年間の結果: ゾレドロン酸アジュバント療法はレトロゾールを服用する閉経後乳癌患者の骨量を維持する

2012 · M Brufsky Adam, Harker W. Graydon, et al. · Cancer (Hoboken, N.J.)

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study

2011 · Noopur Raje, Robert Vescio, et al. · Blood

Works count: 11

Citation count: 370

H-index: 6

I10-index: 5